Seeking Alpha
  • Today - Tuesday, January 27, 2015

  • 9:20 AM
    • Fluidigm (NASDAQ:FLDM) will report Q4 and full-year results on February 5 after the close. The conference call will begin at 5:00 pm ET.
    • Consensus views for Q4 and 2014 are losses per share of ($0.52) and ($2.04) on revenues of $33.3M and $116.3M, respectively.
    | Comment!
  • 9:15 AM
    • Ligand Pharmaceuticals (NASDAQ:LGND) will report Q4 and full-year results on February 9 before the open. The conference call will begin at 9:00 am ET.
    • Consensus views for Q4 and 2014 are EPS of $0.60 and $1.53 on revenues of $23.9M and $65.4M, respectively.
    | Comment!
  • 9:02 AM
    • Accuray (NASDAQ:ARAY) reports fiscal Q2 results today after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is a loss of ($0.08) per share on revenues of $98M.
    | Comment!
  • 8:57 AM
    • GW Pharmaceuticals (NASDAQ:GWPH) will report fiscal Q1 results on February 4 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is a loss per share of ($1.25) on revenues of $12.1M.
    | Comment!
  • 8:43 AM
    • Kindred Healthcare (NYSE:KND) appoints Kent H. Wallace as EVP and Chief Operating Officer effective February 2. He succeeds COO Benjamin A. Breier who will become Chief Executive Officer effective March 31. Mr. Breier succeeds CEO Paul J. Diaz who transition to Executive Vice Chairman.
    • Previously, Mr. Wallace was President and COO at Vanguard Health Systems.
    | Comment!
  • 8:38 AM
    • Incyte (NASDAQ:INCY) will report Q4 and full-year results on February 12 before the open. The conference call will begin at 8:30 am ET.
    • Consensus views for Q4 and 2014 are losses per share of ($0.05) and ($0.13) on revenues of $144.8M and $531.2M, respectively.
    | Comment!
  • 8:32 AM
    | Comment!
  • 8:23 AM
    | Comment!
  • 8:13 AM
    • Bristol-Myers Squibb (NYSE:BMY) Q4 results ($M): Total Revenues: 4,258 (-4.1%); Product Sales: 3,240 (-1.8%); Alliance & Other: 1,018 (-10.9%).
    • COGS: 966 (-24.1%); R&D Expense: 1,189 (+24.2%); SG&A Expense: 1,364 (+3.2%); Net Income: 13 (-98.2%); EPS: 0.01 (-97.7%); Quick Assets: 7,435 (-10.1%).
    • Gross Profit: 3,292 (+3.9%); COGS: 22.7% (-20.9%); Gross Margin: 77.3% (+8.4%); Operating Earnings: 739 (-16.9%); Operating Earnings Yield: 17.4% (-13.3%); Net Earnings Yield: 0.3% (-98.2%).
    • Key Product Sales: Baraclude: 341 (-17.2%); Reyataz: 318 (-17.2%); Sustiva Franchise: 407 (-4.7%); Erbitux: 181 (+0.6%); Sprycel: 398 (+9.0%); Yervoy: 366 (+40.8%); Abilify: 476 (-25.0%); Orencia: 443 (+11.6%); Eliquis: 281 (+295.8%).
    • 2015 Guidance: Revenues: $14.4B - 15.0B; Gross Margin: ~74%; GAAP EPS: $1.55 - 1.70; non-GAAP EPS: $1.55 - 1.70.
    | Comment!
  • 7:43 AM
    • Pfizer (NYSE:PFE) Q4 results ($M): Revenues: 13,118 (-3.2%); GEP: 6,407 (-10.5%); GIP: 3,748 (+2.8%); Global Vaccines: 1,318 (+17.9%); Consumer Health: 953 (+1.1%); Global Oncology: 609 (+9.5%); Other: 83 (-38.5%).
    • COGS: 2,701 (-3.3%); R&D Expense: 3,209 (+77.2%); SI&A Expense: 3,982 (-4.1%); Net Income: 1,228 (-52.2%); EPS: 0.19 (-51.3%).
    • Gross Profit: 10,417 (-3.2%); COGS: 20.6% (-0.1%); Gross Margin: 79.4% (0.0%); Operating Earnings: 3,226 (-32.8%); Operating Earnings Yield: 24.6% (-11.1%); Net Earnings Yield: 9.4% (-50.6%).
    • Key Product Sales: Lyrica: 1,385 (+9.9%), Prevnar Family: 1,301 (+16.3%), Enbrel (ex. US & Canada): 1,004 (-0.1%); Celebrex: 550 (-31.1%); Lipitor: 572 (-6.4%); Viagra: 457 (-4.0%); Zyvox: 343 (-0.9%); Norvasc: 282 (-9.6%); Sutent: 310 (-0.6%); Premarin Family: 290 (-3.0%).
    • 2015 Guidance: Revenues: $44.5B - 46.5B; GAAP EPS: $1.37 - 1.52; non-GAAP EPS: $2.00 - 2.10.
    | 1 Comment
  • 7:32 AM
    • Bristol-Myers Squibb (NYSE:BMY): Q4 EPS of $0.46 beats by $0.05.
    • Revenue of $4.26B (-4.1% Y/Y) beats by $230M.
    • Press Release
    | Comment!
  • 7:13 AM
    • Novartis (NYSE:NVS) Q4 results ($M): Revenues: 14,633 (-3.0%); Pharmaceuticals: 7,860 (-5.6%); Alcon: 2,703 (+1.8%); Sandoz: 2,512 (+4.2%); Vaccines: 494 (-24.6%); Consumer Health: 1,064 (+2.9%).
    • COGS: 5,369 (+1.1%); R&D Expense: 2,753 (+2.1%); SG&A Expense: 3,676 (-23.0%); Net Income: 1,487 (-27.7%); EPS: 0.62 (-24.4%); CF Ops: 5,205 (+17.0%); Quick Assets: 13,862 (+50.3%).
    • Gross Profit: 9,504 (-5.4%); COGS: 36.7% (+4.1%); Gross Margin: 64.9% (-0.2%); Operating Profit: 1,172 (-50.6%); Operating Earnings Yield: 8.0% (-49.1%); Net Earnings Yield: 10.2% (-25.5%).
    • Key Product Sales: Gleevec/Glivec: 1,237 (+0.8%), Gilenya: 666 (+26.4%), Lucentis: 588 (-6.7%), Tasigna: 428 (+21.6%), Afinitor/Votubia: 426 (+18.0%), Sandostatin: 416 (0.0%).
    • 2015 Guidance: Group Net Sales Growth: Mid-single digit; Core Group Operating Income Growth: High-single digit; Pharmaceuticals Growth: Mid-single digit; Alcon Growth: Mid-to-high single digit; Sandoz Growth: Mid-single digit.
    | Comment!
  • 7:03 AM
    • Pfizer (NYSE:PFE): Q4 EPS of $0.54 beats by $0.01.
    • Revenue of $13.12B (-3.2% Y/Y) beats by $170M.
    • Shares -0.21% PM.
    • Press Release
    | Comment!
  • 6:09 AM
    • Novartis (NYSE:NVS): Q4 EPS of $1.21 in-line.
    • Revenue of $14.63B (-2.0% Y/Y) beats by $50M.
    • Shares +1.7% PM.
    • Press Release
    | Comment!
  • Monday, January 26, 2015

  • 6:04 PM
    • Herbalife (NYSE:HLF) will report Q4 and full-year results on February 26 after the close. The conference call will begin at 5:30 pm ET.
    • Consensus views for Q4 and 2014 are EPS of $1.25 and $5.80 on revenues of $1.17B and $4.99B, respectively.
    | 13 Comments
  • 5:57 PM
    • Due to the severe snowstorm, Biogen Idec (NASDAQ:BIIB) moves its Q4 and full-year earnings call to Thursday, January 29 after the close. The webcast will begin at 4:30 pm ET.
    • Previously: Biogen Idec reports January 28 (Dec. 23, 2014)
    | Comment!
  • 4:55 PM
    • Pfizer (NYSE:PFE), through Gavi the Vaccine Alliance, will discount its pneumonia vaccine, Prevenar 13, 20 cents for the world's most resource-limited countries. The per-dose price will drop from $3.30 to $3.10 for the four-dose vial product. The discounted price will be extended to all Gavi-eligible and Gavi-graduated countries through 2025.
    • Previously: Pfizer Prevanar 13 helps to almost halve certain type of pneumonia (March 12, 2014)
    | 6 Comments
  • 4:44 PM
    • Charles River Laboratories International (NYSE:CRL) will report Q4 and full-year results on February 10 after the close. The conference call will begin the next day, February 11, at 9:00 am ET.
    • Consensus views for Q4 and 2014 are EPS of $0.72 and $3.37 on revenues of $318.7M and $1.3B, respectively.
    | Comment!
  • 4:34 PM
    • Neovasc (NASDAQ:NVCN) commences a public offering of 8M shares of common stock, including 1.66M shares offered by certain directors, officers and employees of the company. Underwriters over-allotment is an additional 1.2M shares. Pricing has yet to be announced.
    | Comment!
  • 4:30 PM
    • Epirus Biopharmaceuticals (NASDAQ:EPRS) commences a public offering of common stock. Underwriters over-allotment is an additional 15% of the number of shares offered. Pricing has yet to be announced.
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs